This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

TSC Ratings' Updates: Thoratec

Not only is the stock trading higher than it was a year ago, its rise has outperformed that of the S&P 500 over the same period, despite its weak earnings results. The stock's price rise over the last year has driven it to a level that is somewhat expensive compared with the rest of its industry, but we feel that other strengths this company displays justify these higher price levels.

We've upgraded Thoratec (THOR), which manufactures circulatory support products for use by patients with heart failure, from hold to buy, driven by its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, compelling growth in net income, good cash flow from operations and expanding profit margins. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value.

Revenue rose by 44.2% since the same quarter last year, outperforming the industry average of 15.4% growth and helping boost EPS. The current debt-to-equity ratio, 0.3, is low and is below the industry average, implying successful management of debt levels. The company also maintains a quick ratio of 5.99, which clearly demonstrates the ability to cover short-term cash needs. Net income increased by 610% since the same quarter a year ago, significantly outperforming the S&P 500 and the health care equipment and supplies industry. Net operating cash flow has significantly increased by 111% to $11.9 million when compared with the same quarter last year, vastly surpassing the industry average cash flow growth rate of 21.35%. The company's gross profit margin of 64.8% is rather high, having increased from the same quarter the previous year, though its net profit margin of 8.9% significantly trails the industry average.
4 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
THOR $0.00 0.00%
AME $56.84 0.67%
COVR $5.00 0.07%
GAI $6.00 -2.44%
HOMB $45.10 0.11%


Chart of I:DJI
DOW 17,812.12 -1.27 -0.01%
S&P 500 2,090.85 +1.98 0.09%
NASDAQ 5,126.9210 +10.7780 0.21%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs